REG - Oxford BioDynamics - Result of General Meeting
18/08/2023 11:46
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230818:nRSR8089Ja&default-theme=true
RNS Number : 8089J Oxford BioDynamics PLC 18 August 2023
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER
JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE
MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO
SHAREHOLDERS OF THE COMPANY ON 2 AUGUST 2023.
Oxford BioDynamics PLC
("OBD", the "Company" or together with its subsidiaries, the "Group")
Result of General Meeting
Director/PDMR Dealings
Oxford, UK 18 August 2023 Oxford BioDynamics PLC (AIM: OBD, "OBD" or the
"Company"), a biotechnology company developing precision medicine tests based
on the EpiSwitch® 3D genomics platform, announces that all resolutions
proposed at the general meeting of the Company held earlier today were duly
passed.
Further to the passing of the resolutions at the general meeting of the
Company held earlier today, application has been made for 22,457,268 new
Ordinary Shares (comprising the VCT/EIS Shares to be issued pursuant to the
Placing) to be admitted to trading on the AIM market ("AIM") of the London
Stock Exchange ("VCT/EIS Admission"). Application has also been made for
33,133,767 new Ordinary Shares (comprising the General Placing Shares,
Subscription Shares and PrimaryBid Shares to be issued pursuant to the
Placing, Subscription and PrimaryBid Offer) to be admitted to trading on AIM
("General Admission").
It is expected that VCT/EIS Admission will take place, and trading in the
VCT/EIS Shares will commence, at 8.00 a.m. on 21 August 2023 and that General
Admission will take place, and trading in the General Placing Shares,
Subscription Shares and PrimaryBid Shares will commence at 8.00 a.m. on 22
August 2023.
Following VCT/EIS Admission, the Company's issued ordinary share capital and
total voting rights will consist of 169,169,648 Ordinary Shares. Following
General Admission, the Company's issued ordinary share capital and total
voting rights will consist of 202,303,415 Ordinary Shares. These figures
should be used by shareholders as the denominator for the calculation by which
they determine if they are required to notify their interest in, or a change
to their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
In addition to the Related Party Transactions disclosed in Section 7 of Part I
of the Circular to Shareholders dated 2 August 2023 and the Company's
announcement of 2 August 2023, Dr Alexandre Akoulitchev, Chief Scientific
Officer, subscribed for 300,000 shares in the PrimaryBid Offer. In line with
the intention outlined in the Circular, Paul Stockdale, Chief Financial
Officer, subscribed for 90,909 Ordinary Shares in the PrimaryBid Offer. The
independent directors of the Company (being all of the Directors other than
Alexandre Akoulitchev and Paul Stockdale) having consulted with the Company's
nominated adviser, Shore Capital, consider the terms of Alexandre Akoulitchev
and Paul Stockdale's aggregate subscription for New Ordinary Shares to be fair
and reasonable insofar as the Company's Shareholders are concerned.
The total New Ordinary Shares subscribed for pursuant to the Placing,
Subscription and PrimaryBid Offer by the Directors and PDMRs who are
participating in the Fundraising, are set out below:
Director/PDMR Existing beneficial shareholding Fundraising Shares Beneficial shareholding following the Fundraising Shareholding as a percentage of the Enlarged Issued Share Capital
Dr Alexandre Akoulitchev 6,303,082 300,000 6,603,082 3.26%
Dr Jon Burrows 300,000 400,000 700,000 0.35%
Stephan Diggle* 19,257,847 9,090,909 28,348,756 14.01%
Thomas Guiel 175,000 190,000 365,000 0.18%
Dr Ewan Hunter - 136,363 136,363 0.07%
Paul Stockdale 150,000 181,818 331,818 0.16%
Matthew Wakefield 750,000 272,727 1,022,727 0.51%
* Stephen Diggle's beneficial shareholding is held through the Vulpes Life
Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Director/PDMR Dealings
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Matthew Wakefield
2 Reason for the notification
a) Position/status Chairman
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 272,727
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Jon Burrows
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 400,000
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1
Details of the person discharging managerial responsibilities / person closely
associated
a)
Name
Dr Jon Burrows
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a)
Name
Oxford BioDynamics Plc
b)
LEI
2138005Y1TK258O5U928
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of 1p par value each
ISIN: GB00BD5H8572
b)
Nature of the transaction
Purchase
c)
Price(s) and volume(s)
Price(s) Volume(s)
£0.11 400,000
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Alexandre Akoulitchev
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 300,000
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Paul Stockdale
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 181,818
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Vulpes Investment Management (a PCA of Stephen Diggle) through Vulpes Life
Sciences Fund
2 Reason for the notification
a) Position/status Person closely associated with Non-Executive Director
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 9,090,909
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Thomas Guiel
2 Reason for the notification
a) Position/status Chief Operating Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 190,000
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Ewan Hunter
2 Reason for the notification
a) Position/status Chief Data Officer
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1p par value each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Purchase
c) Price(s) and volume(s) Price(s) Volume(s)
£0.11 136,363
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 18 August 2023
f) Place of the transaction Off market
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
18 August 2023
f)
Place of the transaction
Off market
For more information:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
PrimaryBid Limited enquiries@primarybid.com (mailto:enquiries@primarybid.com)
Fahim Chowdhury/James Deal
Shore Capital - Nominated Adviser Tel: +44 (0)20 7408 4090
Stephane Auton / Iain Sexton
Instinctif Partners - Financial PR Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Rozi Morris / Adam Loudon OxfordBioDynamics@instinctif.com
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.
Its flagship product is EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) for cancer, a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
OBD's next commercial product will be the Prostate Screening EpiSwitch® (PSE)
blood test, due to be launched in Q4 2023.
In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.
The Company has developed a proprietary 3D genomic biomarker platform,
EpiSwitch®, which can build molecular diagnostic classifiers for the
prediction of response to therapy, patient prognosis, disease diagnosis and
subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 10,000 samples in 30 disease areas, and
reduced to practice.
In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMSFDFSAEDSELARecent news on Oxford Biodynamics
See all newsREG - Oxford BioDynamics - Director/PDMR Shareholding
AnnouncementREG - Oxford BioDynamics - PDMR Dealing
AnnouncementREG - Oxford BioDynamics - Result of AGM
AnnouncementREG - Oxford BioDynamics - Board Changes
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
Announcement